169P IMbrave150: Management of adverse events of special interest (AESIs) for atezolizumab (atezo) and bevacizumab (bev) in unresectable HCCM. Kudo,M. Ikeda,A.X. Zhu,S. Qin,T-Y. Kim,H.Y. Lim,V. Breder,P. Merle,A. Kaseb,D. Li,N. Ma,M. Villalobos,S. Stanzel,V.E. Gaillard,D-Z. Xu,S. Hernandez,A-L. Cheng,R.S. Finn,P.R. Galle,M. DucreuxAnnals of Oncology(2020)引用 4|浏览1暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要